Bonnesen Barbara, Jensen Jens-Ulrik Stæhr, Jeschke Klaus Nielsen, Mathioudakis Alexander G, Corlateanu Alexandru, Hansen Ejvind Frausing, Weinreich Ulla Møller, Hilberg Ole, Sivapalan Pradeesh
Department of Medicine, Section of Respiratory Medicine, Herlev and Gentofte Hospital, University of Copenhagen, 2200 Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Diagnostics (Basel). 2021 Dec 2;11(12):2259. doi: 10.3390/diagnostics11122259.
Patients admitted to hospital with coronavirus disease 2019 (COVID-19) may develop acute respiratory failure (ARF) with compromised gas exchange. These patients require oxygen and possibly ventilatory support, which can be delivered via different devices. Initially, oxygen therapy will often be administered through a conventional binasal oxygen catheter or air-entrainment mask. However, when higher rates of oxygen flow are needed, patients are often stepped up to high-flow nasal cannula oxygen therapy (HFNC), continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or invasive mechanical ventilation (IMV). BiPAP, CPAP, and HFNC may be beneficial alternatives to IMV for COVID-19-associated ARF. Current evidence suggests that when nasal catheter oxygen therapy is insufficient for adequate oxygenation of patients with COVID-19-associated ARF, CPAP should be provided for prolonged periods. Subsequent escalation to IMV may be implemented if necessary.
因2019冠状病毒病(COVID-19)入院的患者可能会出现急性呼吸衰竭(ARF),气体交换受损。这些患者需要氧气,可能还需要通气支持,可通过不同设备提供。最初,氧疗通常通过传统的双侧鼻氧导管或空气稀释面罩进行。然而,当需要更高的氧流量时,患者通常会升级为高流量鼻导管氧疗(HFNC)、持续气道正压通气(CPAP)、双水平气道正压通气(BiPAP)或有创机械通气(IMV)。对于COVID-19相关的ARF,BiPAP、CPAP和HFNC可能是IMV的有益替代方案。目前的证据表明,当鼻导管氧疗不足以使COVID-19相关ARF患者充分氧合时,应长期提供CPAP。如有必要,可随后升级为IMV。